A Modelling Approach to Estimate the Impact of Sodium Reduction in Soups on Cardiovascular Health in the Netherlands

Maaike J. Bruins 1,*, Mariska Dötsch-Klerk 2, Joep Matthee 2, Mary Kearney 2, Kathelijn van Elk 2, Peter Weber 3 and Manfred Eggersdorfer 3

1 DSM Biotechnology Center, Alexander Fleminglaan 1, Delft 2613AX, The Netherlands
2 Unilever R&D Vlaardingen, Olivier van Noortlaan 120, Vlaardingen 3133 AT, The Netherlands;
   E-Mails: Mariska.Dotsch@unilever.com (M.D.-K.); Joep.Matthee@unilever.com (J.M.);
   Mary.Kearney@unilever.com (M.K.); Kathelijn-van.Elk@unilever.com (K.E.)
3 DSM Nutritional Products, Wurmisweg 576, Kaiseraugst CH-4303, Switzerland;
   E-Mails: peter.weber@dsm.com (P.W.); manfred.eggersdorfer@dsm.com (M.E.)

* Author to whom correspondence should be addressed; E-Mail: maaike.bruins@DSM.com;
   Tel.: +31-62-563-8227; Fax: +31-15-279-4110.

Received: 24 July 2015 / Accepted: 6 September 2015 / Published: 17 September 2015

Abstract: Hypertension is a major modifiable risk factor for cardiovascular disease and mortality, which could be lowered by reducing dietary sodium. The potential health impact of a product reformulation in the Netherlands was modelled, selecting packaged soups containing on average 25% less sodium as an example of an achievable product reformulation when implemented gradually. First, the blood pressure lowering resulting from sodium intake reduction was modelled. Second, the predicted blood pressure lowering was translated into potentially preventable incidence and mortality cases from stroke, acute myocardial infarction (AMI), angina pectoris, and heart failure (HF) implementing one year salt reduction. Finally, the potentially preventable subsequent lifetime Disability-Adjusted Life Years (DALYs) were calculated. The sodium reduction in soups might potentially reduce the incidence and mortality of stroke by approximately 0.5%, AMI and angina by 0.3%, and HF by 0.2%. The related burden of disease could be reduced by approximately 800 lifetime DALYs. This modelling approach can be used to provide insight into the potential public health impact of sodium reduction in specific food products. The data demonstrate that an achievable food product reformulation to reduce sodium can potentially benefit public health, albeit modest. When implemented across multiple product categories and countries, a significant health impact could be achieved.
1. Introduction

High blood pressure is the 5th leading risk factor of the global burden of disease in terms of Disability-Adjusted Life Years (DALYs) [1]. Blood pressure is known to be a major modifiable risk factor for cardiovascular disease, including stroke and Ischemic Heart Disease (IHD) [2,3]. Randomized controlled trials have demonstrated that reducing sodium intake lowers blood pressure in a linear way [4,5]. Moreover, evidence from prospective cohort studies indicates a relationship between higher levels of sodium intake and increased risk of cardiovascular disease [5]. Therefore, it is assumed that reductions in sodium ultimately result in lower risk of cardiovascular disease.

The estimated mean global daily intake of 4 g sodium (10 g salt) [6] largely exceeds the current World Health Organization (WHO) daily recommendation of less than 2 g sodium (5 g salt) [7]. Reducing sodium intakes is therefore a recognized public health priority of health authorities and non-governmental organizations. In European and North American countries, generally over 75% of sodium intake comes from food products (mostly meat, bread and other cereal products, but also cheese and soups). In contrast, in Asian countries discretionary salt contributes most to sodium intake [8].

Reducing sodium in food products represents a technical challenge as salt is added to food to enhance taste, increase product shelf life and improve texture [9]. Consumers may not accept significantly lower salt levels in food products as was shown for soups [10]. The most promising strategy is to adapt consumer’s preferences for saltiness by reducing sodium in products in small steps [10]. However, this approach needs governmental and non-governmental organizations, health care professionals, and the food industry to collaborate in order to be effective. Therefore, the food industry is also exploring other solutions to limit sodium content in food products in order to provide healthier products that help people improve their health. Examples include the use of mineral salts with less or no sodium, and natural taste enhancers such as yeast extracts, aromas, and spices. Currently applied approaches are resulting in sodium reductions between 20%–30% depending on the application [11]. A joint effort to reformulate food products to reduce the levels of salt will help consumers achieving a healthier diet.

In this paper, to explore the potential health impact of a potentially achievable sodium reduction in a specific food, a modelling approach was applied to estimate the preventable DALYs related to cardiovascular disease. In this modelling study, sodium reduction in packaged soups in the Netherlands was selected as a widely consumed food category in which successful sodium reduction can be achieved if carried out gradually and industry-wide.

2. Modelling Methods

Data from the Dutch National Food Consumption Survey 2007–2010 [12] and the Dutch Food Composition Database 2011 [13] were used to collect data on average soup consumption, and sodium content of soup, respectively. An average 25% sodium reduction in soup, was considered achievable over time when executed gradually [14]. The effect of 25% sodium reduction in soup in 2011 on
cardiovascular-related morbidity and mortality in that year and subsequent lifetime effects was simulated for the adult Dutch population aged ≥ 20 years with a size of 12.7 million people (49% men, 51% women).

As a first step, the dose-response relationship between changes in sodium intake and changes in Systolic Blood Pressure (SBP) was derived from a recent meta-analysis by He et al. [15] showing that per 4.4 g/day reduction in salt intake (as measured by urinary sodium excretion), SBP decreases on average by 4.18 mmHg. The reductions in incidence of stroke, AMI and angina pectoris events in relation to SBP lowering were derived from Relative Risk Reductions reported per 10-years age group in a meta-analysis by Law et al. [2]. Systolic Blood Pressure-related reductions in mortality from stroke, AMI and angina were derived from a meta-analysis by Lewington et al. [3]. The reduction in SBP related incidence and mortality of Heart Failure (HF) was derived from Relative Risk Reductions reported in different studies [16–21]. For the different age groups, a log-linear relation between SBP lowering and reduction of disease mortality and incidence was assumed [3].

The DALY can be used to assess health impact; the DALY combines mortality and morbidity into a single, quantitative metric. The health burden is the sum of years of life lost due to premature mortality (YLL) and morbidity (years lived with disability; YLD). The WHO method [22] and calculation template [23] were used to calculate DALYs due to cardiovascular disease-related morbidity and mortality. The potential DALYs prevented when reducing sodium in soup were calculated as the difference in DALYs between the scenario without and with salt reduction.

Global disease disability weights and data on the population size and life expectancies, cardiovascular disease-specific incidence cases, mortality cases, and durations as reported for the Netherlands in 2011 served as inputs for the model. These data were extracted from the Statistics Netherlands (CBS) [24] and Volksgezondheid en Zorg [25] databases, all per gender and 10-year age group ≥ 20 years. Incidence data on cardiovascular morbidity and mortality were available for stroke (ICD-10-code I60-I69), HF (ICD-10-code I50), AMI (ICD-10-code I21-I22) and angina (ICD-10-code I20). Incidents of AMI and angina were based on reported incidence trends for AMI and angina in 2011 [25]. Stroke was assumed reversible and disability to last six months in 65% of patients, and leading to permanent moderate to severe disability in 35% of patients [26]. Netherlands-specific data were collected on time lived with an acute disability (hospital stay) for stroke [27] and AMI [28], and time lived with a permanent disability for stroke, angina, and HF were derived by dividing prevalence rates by incidence rates [25]. Frequency-weighted average disability weights for the hyperacute and acute phase of stroke [29], the hyperacute and acute phase of AMI [29], and chronic disability for angina [30] and HF [30] were based on results of Global Burden of Disease (GBD) 2010, and for disabled stroke survivors, based on GBD 2004 results [29]. Discount rate and age weight were not applied as these were recently dropped following informal consultations in 2012 by WHO [31].

3. Results

The median daily soup consumption of the Dutch population ≥ 20 years was 52.4 g with comparable consumption among age groups and genders. Given that soups in 2011 in the Netherlands contained on average 340 mg/100 g sodium, this would reflect a median daily intake of 180 mg sodium (0.46 g salt) from soup. An average of 25% sodium reduction in soups would reduce median population sodium
intake by 45 mg/day (i.e., salt by 0.11 g/day). Based on the dose-response relationship reported between salt intake and SBP, a 45 mg/day lower sodium intake could reduce the average SBP by 0.11 mmHg.

Based on reported Relative Risk Reductions, a reduction in SBP of 0.11 mm Hg could reduce the stroke-related incidence by (age-weighted average) 0.49%, AMI and angina incidence by 0.34%, and HF incidence by 0.24%. A 0.11 mmHg reduction was estimated to reduce on average the stroke-related mortality by 0.46%, AMI and angina mortality by 0.34%, and HF mortality by 0.24%. The related number of potential cases averted is shown in Table 1.

**Table 1.** Estimate of potentially avertable mortality and morbidity incidence cases in the 2011 Dutch population cohort aged ≥20 years, if reducing sodium in soups by 25%.

|                     | Males | Females | Total |
|---------------------|-------|---------|-------|
| Total mortality     | 24    | 23      | 47    |
| Stroke incidence    | 49    | 46      | 95    |
| AMI incidence       | 56    | 29      | 85    |
| Angina incidence    | 41    | 29      | 70    |
| HF incidence        | 17    | 20      | 37    |

AMI: acute myocardial infarction; HF: heart failure.

The number of years of life lost due to premature mortality and years lived with the disease, and the total number of DALYs in the Dutch population that could potentially be averted by a 45 mg/day sodium reduction in soups are presented in Table 2. Mainly preventable stroke and angina with long-term consequences contributed to the preventable YLD whereas acute stroke and AMI contributed little considering their short-term nature (data not shown).

**Table 2.** Estimate of potentially avertable number of years of life lost (YLL), years lived with disability (YLD) and disability-adjusted life years (DALYs) (at 0% discount rate, 0% age weight) in the 2011 Dutch population cohort aged ≥20 years, if reducing sodium in soups by 25%.

|        | Males | Females | Total |
|--------|-------|---------|-------|
| YLL    | 341   | 257     | 598   |
| YLD    | 123   | 98      | 221   |
| DALYs  | 464   | 355     | 819   |

YLL: Years of Life Lost; YLD: Years Lived with Disability; DALY: Disability-Adjusted Life Years.

4. Discussion

This modelling study indicates that an average salt reduction in soups of 25% in The Netherlands in one year could potentially save approximately 800 lifetime DALYs related to cardiovascular disease.
Widespread recommendations to reduce salt intake with the purpose of promoting public health have led to specific global and national targets for reducing salt in manufactured foods [32]. In order to achieve these targets, small and large commitment from food industries to collectively reformulate foods is of key importance. Today, many food industries are engaged in sodium reduction, but, in many countries, salt intake is still exceeding the recommendations [32]. More commitments and partnerships are required to get intakes closer to the recommendations. Estimating the potential impact of specific initiatives can help encourage more stakeholders for greater engagement in salt reduction.

Salt reduction in soups in The Netherlands was selected as a practical example of a product group and country where data are available and sodium reduction is genuinely happening. This allows for an assessment of what impact a realistic sodium reduction in a specific food group can have on public health. An average reduction of 25% in soups is considered potentially feasible on the longer term (stressing that this concerns an average reduction of 25% as not all soups have the same sodium level, so cannot be reduced with the same amount) [14]. However, such a reduction is only achievable when executed in small steps as consumers will not accept too drastic changes in taste or may even add back salt themselves [10].

In this modelling study, demographics and most recent cardiovascular morbidity and mortality data from The Netherlands were used as model inputs to estimate the gain in health from salt reduction in soup. Although salt lowering might also reduce the risk related to stomach cancer [33] and chronic kidney disease [34], the data available are not sufficient to properly estimate the potential impact of salt reduction on these health outcomes.

In the current analysis, a linear relationship between salt restriction and SBP lowering was assumed as based on a meta-analysis of intervention trials in which sodium reduction was in the middle range (0.9–2.7 g/day) [15]. However, SBP lowering may not be fully linear across the range of reduced sodium intakes, smaller effects being achieved with smaller reductions, and larger effects achieved with larger reductions [35]. A premise of the current analysis is that sodium reduction from soups (45 mg/day) is part of a broader initiative of medium sodium reduction to reach the threshold for achieving a meaningful SBP reduction.

As this is a modelling approach which has its limitations, some care should be taken interpreting the findings. For instance, the estimated risk reductions were derived from relative risk reductions reported in multiple international studies, and therefore not specific for the Netherlands. In addition, relative risk reductions for cardiovascular incidence and mortality associated with SBP lowering were modelled for age groups for which no relative risk reduction was reported. Stroke is a complex syndrome including multiple types and subtypes with varying causes and outcomes, but we tried to address this as much as possible by modelling stroke with acute, medium and long-term entities.

It should also be noted that the estimate of burden of disease depends on the selected method. We selected the WHO calculation template that provides rough DALY estimates and is restricted to predicting prospective morbidity and mortality in a one-year population cohort. More sophisticated (dynamic or stochastic) Monte Carlo-based disease progression mathematical models, exist that simulate long-term effects of interventions by calculating cumulative incidence and mortality, changes in life expectancy, transition between disease states, and provide uncertainty ranges in the final DALY result.
Previous modelling studies have also shown a positive public health impact of salt reduction strategies \([36–40]\). However, as the studies differ in scenarios, inputs and methodology, direct comparisons are difficult to make. Hendriksen et al. \([36]\) also simulated the health impact of salt-reduction on the adult Dutch population aged \(\geq 20\) years. The authors used similar output variables (incidence and mortality of stroke, AMI, and HF), but used salt reduction scenario’s related to larger reductions in salt intake (2.3 to 3.0 g/day). In addition, the impact of salt reduction was simulated over a 20-years period using a more sophisticated model \([36]\). However, when similar reductions in salt intake were assumed in our model, comparable estimations of potential incidence cases averted in the first year were obtained, supporting the validity of our results. Health impact modelling in the domain of public health nutrition is still in its infancy, and there is strong need for further alignment and accessibility of practical and valid models to enable robust impact assessment of public health strategies, including product reformulation.

5. Conclusions

This is the first study that has estimated the potential public health impact of a substantial salt reduction in a single food category. Since considerable acute and long-term health care costs and productivity losses are involved with HF, stroke \([41]\) and AMI \([42]\), it is likely that reducing respective incident cases can significantly reduce related health care costs and productivity losses. This case study shows that a substantial and achievable salt reduction in soups in the Netherlands as part of an overall salt reduction strategy, could potentially have an impact, albeit small, on public health. Provided a cohesive industry-wide total diet approach is adopted, implying that sodium reduction is executed in more product groups and countries, small changes can add up to make a big difference.

Supplementary Materials

Supplementary Materials are provided on the Modelling approach, and inputs and outputs (Table S1–Table S24, Figure S1–S3). Tables S1–S3 show the demographics data that were collected for The Netherlands in 2011. Table S4 shows the case fatality rates for the Netherlands in 2001 and Table S5 the estimated percentage of patients suffering from a disability.

Acknowledgments

No external funding was provided for this work.

Author Contributions

Maaike Bruins was involved in the collection, assembly, analysis and generation of data. Maaike Bruins, Mariska Dötsch-Klerk, and Joep Matthee drafted the manuscript. Mary Kearney, Kathelijn van Elk, Peter Weber, and Manfred Eggersdorfer were involved in modelling discussions and revisions of the manuscript. All authors have been involved in manuscript preparation and have approved the submitted manuscript.
Conflicts of Interest

Financial support and conflict of interest: Maaike Bruins, Peter Weber, and Manfred Eggersdorfer are employed by DSM and Mariska Dötsch-Klerk, Joep Matthee, Mary Kearney, and Kathelijn van Elk are employed by Unilever; DSM and Unilever provided funding for this study.

References

1. Health Statistics and Information Systems. Global Health Risks; Part 2. Results; World Health Organization (WHO): Geneva, Switzerland, 2009.
2. Law, M.R.; Morris, J.K.; Wald, N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338, b1665. [CrossRef] [PubMed]
3. Lewington, S.; Clarke, R.; Qizilbash, N.; Peto, R.; Collins, R.; Prospective Studies, C. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360, 1903–1913. [CrossRef]
4. Mozaffarian, D.; Fahimi, S.; Singh, G.M.; Micha, R.; Khatibzadeh, S.; Engell, R.E.; Lim, S.; Danaei, G.; Ezzati, M.; Powles, J.; et al. Global sodium consumption and death from cardiovascular causes. NEJM 2014, 371, 624–634. [CrossRef] [PubMed]
5. Sodium Intake in Populations. In Assessment of Evidence; Institute of Medicine: Washington, DC, USA, 2013.
6. Powles, J.; Fahimi, S.; Micha, R.; Khatibzadeh, S.; Shi, P.; Ezzati, M.; Engell, R.E.; Lim, S.S.; Danaei, G.; Mozaffarian, D.; et al. Global, regional and national sodium intakes in 1990 and 2010: A systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 2013, 3, e003733. [CrossRef] [PubMed]
7. World Health Organization (WHO). Guideline: Sodium Intake for Adults and Children; World Health Organization (WHO): Geneva, Switzerland, 2012.
8. Brown, I.J.; Tzoulaki, I.; Candeias, V.; Elliott, P. Salt intakes around the world: Implications for public health. Int. J. Epidemiol. 2009, 38, 791–813. [CrossRef] [PubMed]
9. Institute of Medicine (US) Committee on Strategies to Reduce Sodium Intake. Strategies to Reduce Sodium Intake in the United States; Appendix D: Salt Substitutes and Enhancers; Institute of Medicine (US) Committee on Strategies to Reduce Sodium Intake: Washington, DC, USA, 2010.
10. Liem, D.G.; Miremadi, F.; Zandstra, E.H.; Keast, R.S. Health labelling can influence taste perception and use of table salt for reduced-sodium products. Public Health Nutr. 2012, 15, 2340–2347. [CrossRef] [PubMed]
11. Dotsch, M.; Busch, J.; Batenburg, M.; Liem, G.; Tareilus, E.; Mueller, R.; Meijer, G. Strategies to reduce sodium consumption: A food industry perspective. Crit. Rev. Food Sci. Nutr. 2009, 49, 841–851. [CrossRef] [PubMed]
12. Van Rossum, C.T.M.; Fransen, H.P.; Verkaik-Kloosterman, J.; Buurman, E.M.; Ocké, M.C. Dutch National Food Consumption Survey 2007–2010: Diet of Children and Adults Aged 7 to 69 Years; National Institute for Public Health and the Environment (RIVM): Bilthoven, The Netherlands, 2011.
13. Dutch food composition database. Nevo Online Version 2011/3.0. Available online: http://www.rivm.nl/en/Topics/Topics/D/Dutch_Food_Composition_Database (accessed on 13 July 2015).

14. Dotsch-Klerk, M.; Pmm Goossens, W.; Meijer, G.W.; van Het Hof, K.H. Reducing salt in food; setting product-specific criteria aiming at a salt intake of 5 g per day. *Eur. J. Clin. Nutr.* **2015**, *69*, 799–804. [CrossRef] [PubMed]

15. He, F.J.; Li, J.; Macgregor, G.A. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. *BMJ* **2013**, *346*, f1325. [CrossRef] [PubMed]

16. Vaccarino, V.; Holford, T.R.; Krumholz, H.M. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. *J. Am. Coll. Cardiol.* **2000**, *36*, 130–138. [CrossRef]

17. Chae, C.U.; Pfeffer, M.A.; Glynn, R.J.; Mitchell, G.F.; Taylor, J.O.; Hennekens, C.H. Increased pulse pressure and risk of heart failure in the elderly. *JAMA* **1999**, *281*, 634–639. [CrossRef]

18. Haider, A.W.; Larson, M.G.; Franklin, S.S.; Levy, D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the framingham heart study. *Ann. Intern. Med.* **2003**, *138*, 10–16. [CrossRef] [PubMed]

19. Britton, K.A.; Gaziano, J.M.; Djousse, L. Normal systolic blood pressure and risk of heart failure in US male physicians. *Eur. J. Heart Fail.* **2009**, *11*, 1129–1134. [CrossRef] [PubMed]

20. Rapsomaniki, E.; Timmis, A.; George, J.; Pujades-Rodriguez, M.; Shah, A.D.; Denaxas, S.; White, I.R.; Caulfield, M.J.; Deanfield, J.E.; Smeeth, L.; *et al*. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. *Lancet* **2014**, *383*, 1899–1911. [CrossRef]

21. Kalogeropoulos, A.P.; Georgiopoulou, V.V.; Agha, S.A.; Grigorios, G.; Smith, A.L.; Kritchevsky, S.B.; Najjar, S.; Bibbins-Domingo, K.; Sutton-Tyrrell, K.; Harris, T.B.; *et al*. Systolic blood pressure and heart failure risk in the elderly: The health, aging, and body composition study. *Circulation* **2009**, *120*, S505–S506.

22. Prüss-Üstün, A.; Mathers, C.; Corvalán, C.; Woodward, A. Introduction and Methods: Assessing the Environmental Burden of Disease at National and Local Levels, Chapter 3. In *The Global Burden of Disease Concept*; World Health Organization (WHO): Geneva, Switzerland, 2003; pp. 27–40.

23. Health Statistics and Health Information Systems. Available online: http://www.who.int/healthinfo/global_burden_disease/tools_national/en/ (accessed on 13 July 2015).

24. Statline. Available online: http://statline.cbs.nl/Statweb/ (accessed on 13 July 2015).

25. Feiten en Cijfers over Volksgezondheid en Zorg. Available online: https://www.volksgezondheidenzorg.info/ (accessed on 13 July 2015).

26. Lingsma, H.F.; Steyerberg, E.W.; Eijkemans, M.J.; Dippel, D.W.; Scholte Op Reimer, W.J.; van Houwelingen, H.C. Comparing and ranking hospitals based on outcome: Results from The netherlands stroke survey. *QJM* **2010**, *103*, 99–108. [CrossRef] [PubMed]

27. Hart-en Vaatziekten in Nederland 2012. Cijfers over Risicofactoren, Ziekte en Sterfte. Available online: http://webshop.hartstichting.nl/Producten/Producten.aspx (accessed on 15 July 2015).
28. Organisation for Economic Cooperation and Development (OECD). *Health at a Glance 2013: Oecd Indicators*; Organisation for Economic Cooperation and Development (OECD): Paris, France, 2013.

29. Hong, K.S.; Saver, J.L. Quantifying the value of stroke disability outcomes: Who global burden of disease project disability weights for each level of the modified rankin scale. *Stroke* 2009, 40, 3828–3833. [CrossRef] [PubMed]

30. Moran, A.E.; Forouzanfar, M.H.; Roth, G.A.; Mensah, G.A.; Ezzati, M.; Flaxman, A.; Murray, C.J.; Naghavi, M. The global burden of ischemic heart disease in 1990 and 2010: The global burden of disease 2010 study. *Circulation* 2014, 129, 1493–1501. [CrossRef] [PubMed]

31. World Health Organization (WHO) Department of Health Statistics and Information Systems. *Who Methods and Data Sources for Global Burden of Disease 2000–2011*; World Health Organization (WHO) Department of Health Statistics and Information Systems: Geneva, Switzerland, 2013.

32. Webster, J.; Trieu, K.; Dunford, E.; Hawkes, C. Target salt 2025: A global overview of national programs to encourage the food industry to reduce salt in foods. *Nutrients* 2014, 6, 3274–3287. [CrossRef]

33. D’Elia, L.; Galletti, F.; Strazzullo, P. Dietary salt intake and risk of gastric cancer. *Cancer Treat. Res.* 2014, 159, 83–95. [PubMed]

34. Aaron, K.J.; Sanders, P.W. Role of dietary salt and potassium intake in cardiovascular health and disease: A review of the evidence. *Mayo Clin. Proc.* 2013, 88, 987–995. [CrossRef] [PubMed]

35. Mente, A.; O’Donnell, M.J.; Rangarajan, S.; McQueen, M.J.; Poirier, P.; Wielgosz, A.; Morrison, H.; Li, W.; Wang, X.; Di, C.; et al. Association of urinary sodium and potassium excretion with blood pressure. *NEJM* 2014, 371, 601–611. [CrossRef] [PubMed]

36. Hendriksen, M.A.; Hoogenveen, R.T.; Hoekstra, J.; Geleijnse, J.M.; Boshuizen, H.C.; van Raaij, J.M. Potential effect of salt reduction in processed foods on health. *Am. J. Clin. Nutr.* 2014, 99, 446–453. [CrossRef] [PubMed]

37. Bibbins-Domingo, K.; Chertow, G.M.; Coxson, P.G.; Moran, A.; Lightwood, J.M.; Pletcher, M.J.; Goldman, L. Projected effect of dietary salt reductions on future cardiovascular disease. *NEJM* 2010, 362, 590–599. [CrossRef] [PubMed]

38. Cobiac, L.J.; Vos, T.; Veerman, J.L. Cost-effectiveness of interventions to reduce dietary salt intake. *Heart* 2009, 96, 1920–1925. [CrossRef] [PubMed]

39. Dodhia, H.; Phillips, K.; Zannou, M.I.; Airoldi, M.; Bevan, G. Modelling the impact on avoidable cardiovascular disease burden and costs of interventions to lower sbp in the England population. *J. Hypertens.* 2012, 30, 217–226. [CrossRef] [PubMed]

40. Nghiem, N.; Blakely, T.; Cobiac, L.J.; Pearson, A.L.; Wilson, N. Health and economic impacts of eight different dietary salt reduction interventions. *PLoS ONE* 2015, 10, e0123915. [CrossRef] [PubMed]

41. Van Exel, J.; Koopmanschap, M.A.; van Wijngaarden, J.D.; Scholte Op Reimer, W.J. Costs of stroke and stroke services: Determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. *Cost Eff. Resour. Alloc.* 2003, 1, 2. [CrossRef] [PubMed]
42. Soekhlal, R.R.; Burgers, L.T.; Redekop, W.K.; Tan, S.S. Treatment costs of acute myocardial infarction in The Netherlands. *Neth. Heart J.* 2013, 21, 230–235. [CrossRef] [PubMed]

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).